JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
139.50
+0.04 (+0.03%)
At close: 4:03PM EDT

139.51 +0.01 (0.01%)
After hours: 7:30PM EDT

Stock chart is not supported by your current browser
Previous Close139.46
Open139.20
Bid0.00 x 1400
Ask0.00 x 1800
Day's Range137.71 - 139.81
52 Week Range118.62 - 148.32
Volume7,584,163
Avg. Volume6,179,647
Market Cap374.245B
Beta (3Y Monthly)0.53
PE Ratio (TTM)277.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2018-08-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Stocks can keep rallying as long as Fed doesn't keep push...
    CNBC Videos2 days ago

    Stocks can keep rallying as long as Fed doesn't keep push...

    Jim Cramer explains what led the market to soar on Tuesday after days of selling and says the strength can last if the Fed behaves accordingly.

  • Cramer: As long as the Fed doesn't keep pushing rate hike...
    CNBC Videos2 days ago

    Cramer: As long as the Fed doesn't keep pushing rate hike...

    Jim Cramer explains what led the market to soar on Tuesday after days of selling and says the strength can last if the Fed behaves accordingly.

  • Motley Fool2 hours ago

    Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?

    How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.

  • Investing.com3 hours ago

    Intuitive Surgical Earnings miss, Revenue beats In Q3

    Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.

  • Pfizer’s Growth Rate and Estimates
    Market Realist7 hours ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
    Zacks8 hours ago

    Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch

    Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist9 hours ago

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realist10 hours ago

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segment—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • Analyzing Pfizer’s Stock Performance in October
    Market Realist10 hours ago

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Motley Foolyesterday

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.

  • They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more
    American City Business Journalsyesterday

    They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more

    After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.

  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of JNJ earnings conference call or presentation 16-Oct-18 12:30pm GMT

    Q3 2018 Johnson & Johnson Earnings Call

  • Investing.comyesterday

    Abbott Labs Earnings, Revenue beat in Q3

    Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.

  • Stock Market News For Oct 17, 2018
    Zacks2 days ago

    Stock Market News For Oct 17, 2018

    Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.

  • Asian shares climb on strong US corporate earnings, data
    Associated Press2 days ago

    Asian shares climb on strong US corporate earnings, data

    SINGAPORE (AP) — Asian markets rose on Wednesday as robust U.S. corporate earnings and encouraging data assuaged worries about softening global growth.

  • TheStreet.com2 days ago

    The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)

    "When the Fed bears are away, the stock bulls will play," Jim Cramer told his Mad Money viewers Tuesday, after the markets mounted an impressive relief rally. Cramer reminded viewers that a panic is a terrible thing to waste, which is why the smart money was buying into the recent declines and not selling out of fear.

  • The Wall Street Journal2 days ago

    [$$] Prescription Drugs Power Johnson & Johnson Results

    Johnson & Johnson reported higher revenue and profit for the third quarter, as improved pharmaceutical sales helped offset weakness in its medical-device business. Global sales of J&J’s cancer drugs, which include Zytiga for prostate cancer and blood-cancer treatments Darzalex and Imbruvica, jumped 36% for the quarter. “Our positive view on pharma is offset by ongoing challenges to the company’s medical device and consumer franchises,” JPMorgan analyst Chris Schott wrote in a research note.

  • The Wall Street Journal2 days ago

    [$$] Encouraging Test Results for Health-Care Giants

    Another round of strong earnings suggests that health care is living up to its reputation as a defensive industry. UnitedHealth Group and Johnson & Johnson, two industry heavyweights, demonstrated that with third-quarter results on Tuesday by topping analyst expectations on both the top and bottom line and increasing their full year profit guidance. UnitedHealth, the nation’s largest publicly traded health insurer, reported revenue of $56.5 billion and adjusted earnings of $3.41 a share.

  • TheStreet.com2 days ago

    Jim Cramer: An Absence of Negatives Is a Real Positive

    This is what the market looks like when the Fed says nothing and the president isn't ranting about something involving Jay Powell or China. You wouldn't get this straight up move but as I explained in a video with Katherine Ross this morning, yesterday we hit minus seven on the S&P's proprietary oscillator, which is about as negative as we have gotten during this period and that means you have to find something to buy no matter what. Initially Walmart was down off of the numbers because they weren't adjusted for Flipkart but because everyone's so negative.

  • CNBC2 days ago

    Cramer: As long as the Fed doesn't keep pushing rate hikes, stocks can keep rallying

    CNBC's Jim Cramer explains what led the market to soar on Tuesday after days of selling. The strength can last as long as the Fed doesn't get too hawkish, the "Mad Money" host warns. As better-than-expected earnings results drove the Dow Jones Industrial Average more than 500 points higher on Tuesday, paring last week's losses, CNBC's Jim Cramer became cautiously optimistic about the fate of the rally.

  • 3 Stocks for Warren Buffett Fans
    Motley Fool2 days ago

    3 Stocks for Warren Buffett Fans

    If you want to be like Buffett, here's a healthcare stock, an auto company, and an airline for you.

  • What Happened in the Stock Market Today
    Motley Fool2 days ago

    What Happened in the Stock Market Today

    Stocks bounced back, with investors encouraged by earnings reports from companies like Morgan Stanley and Johnson & Johnson.

  • Investopedia2 days ago

    Stocks Soar on Earnings Octane

    Suddenly, higher interest rates, political instability, tariff troubles and an earnings slowdown seemed like, well, yesterday’s news. Banks like Goldman Sachs and Morgan Stanley reported better than expected results, sending their shares higher. Johnson & Johnson, a DJIA component and a great proxy for consumer spending, also beat expectations.

  • Associated Press2 days ago

    UnitedHealth, Johnson & Johnson and Morgan Stanley jump

    Stocks that moved substantially or traded heavily on Tuesday: Johnson & Johnson, up $2.61 to $136.56 The health care products company reported higher sales of prescription drugs. Goldman Sachs Group Inc., ...

  • CNBC2 days ago

    Market focuses on revenue growth as the key to combating rising costs, interest rates

    Tuesday's big movers, including Goldman Sachs, Morgan Stanley, Comerica, UnitedHealth and Johnson & Johnson, all beat by wide margins. Fear of higher costs, through higher interest rates, higher wages and higher raw material costs, has now become a major preoccupation for investors. Tuesday's big movers, including Goldman Sachs GS , Morgan Stanley MS , Comerica CMA , UnitedHealth UNH and Johnson & Johnson JNJ , all beat by wide margins.